tiprankstipranks
Trending News
More News >

Cizzle Biotechnology Appoints New CSO Amidst Lung Cancer Test Advancements

Story Highlights
Cizzle Biotechnology Appoints New CSO Amidst Lung Cancer Test Advancements

Don’t Miss TipRanks’ Half-Year Sale

An update from Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) is now available.

Cizzle Biotechnology has appointed Professor Dawn Coverley as Chief Scientific Officer to enhance its global licensing and partnership strategy. This move coincides with the successful technical completion of the CIZ1B biomarker assay, poised to become a scalable solution for early lung cancer detection, potentially impacting the company’s market reach and patient care standards.

More about Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer specializing in a non-invasive, cost-effective blood test using the CIZ1B biomarker for early lung cancer detection. The company focuses on commercial royalty-bearing arrangements for its proprietary technology and collaborations with cancer care centers.

Average Trading Volume: 617,025

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £6.14M

See more data about CIZ stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1